metaPreg - Primidone (Epilepsy) during pregnancy

Primidone (Epilepsy)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.88 [1.39, 5.95]	10%	9 studies	151	152	not evaluable	ROB	5.20 [2.13; .]
Major congenital malformations	2.66 [1.03, 6.86]	22%	7 studies	134	113	not evaluable	ROB	4.76 [1.22; .]
Minor congenital malformations	3.46 [0.38, 31.70]	0%	2 studies	12	33	not evaluable	ROB	-
Neural Tube Defects	1.01 [0.06, 17.08]	0%	2 studies	1	41	not evaluable	ROB	-
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	25.60 [2.59, 252.91]	-	1 study	5	14	not evaluable	ROB	50.70 [4.62; .]
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	2.15 [0.15, 30.90]	0%	2 studies	4	4	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study